U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Densely Granulated Somatotroph Pituitary Neuroendocrine Tumor

MedGen UID:
310676
•Concept ID:
C1707675
•
Neoplastic Process
Synonyms: Densely Granulated Pituitary Gland Somatotroph Adenoma; Densely Granulated Somatotroph PitNET/Adenoma; Densely Granulated Somatotroph Pituitary Neuroendocrine Tumor/Adenoma

Definition

A growth hormone-producing pituitary neuroendocrine tumor composed of medium-sized acidophilic cells with granular cytoplasm and abundant secretory granules. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVDensely Granulated Somatotroph Pituitary Neuroendocrine Tumor

Professional guidelines

PubMed

Clinical, hormonal and pathomorphological markers of somatotroph pituitary neuroendocrine tumors predicting the treatment outcome in acromegaly.
Tomasik A, Stelmachowska-Banaś M, Maksymowicz M, Czajka-Oraniec I, Raczkiewicz D, Zieliński G, Kunicki J, Zgliczyński W
Front Endocrinol (Lausanne) 2022;13:957301. Epub 2022 Sep 16 doi: 10.3389/fendo.2022.957301. PMID: 36187106Free PMC Article
MANAGEMENT OF ENDOCRINE DISEASE: Etiology and outcome of acromegaly in patients with a paradoxical GH response to glucose.
Hage M, Janot C, Salenave S, Chanson P, Kamenický P
Eur J Endocrinol 2021 May 10;184(6):R261-R268. doi: 10.1530/EJE-20-1448. PMID: 33830942
Pathological markers of somatotroph pituitary neuroendocrine tumors predicting the response to medical treatment.
Trouillas J, Vasiljevic A, Lapoirie M, Chinezu L, Jouanneau E, Raverot G
Minerva Endocrinol 2019 Jun;44(2):129-136. Epub 2018 Dec 7 doi: 10.23736/S0391-1977.18.02933-4. PMID: 30531694

Recent clinical studies

Etiology

Clinicopathological Analysis of Densely and Sparsely Granulated Somatotroph Tumors of Pituitary.
Wang L, He X, Lu L, Chen L, Peng C, Shao C, Ge R
World Neurosurg 2024 May;185:e713-e720. Epub 2024 Feb 24 doi: 10.1016/j.wneu.2024.02.115. PMID: 38408701
Transcriptomic Classification of Pituitary Neuroendocrine Tumors Causing Acromegaly.
Rymuza J, Kober P, Rusetska N, Mossakowska BJ, Maksymowicz M, Nyc A, Baluszek S, Zieliński G, Kunicki J, Bujko M
Cells 2022 Nov 30;11(23) doi: 10.3390/cells11233846. PMID: 36497102Free PMC Article
Clinical, hormonal and pathomorphological markers of somatotroph pituitary neuroendocrine tumors predicting the treatment outcome in acromegaly.
Tomasik A, Stelmachowska-Banaś M, Maksymowicz M, Czajka-Oraniec I, Raczkiewicz D, Zieliński G, Kunicki J, Zgliczyński W
Front Endocrinol (Lausanne) 2022;13:957301. Epub 2022 Sep 16 doi: 10.3389/fendo.2022.957301. PMID: 36187106Free PMC Article
Predictive Factors of Somatostatin Receptor Ligand Response in Acromegaly-A Prospective Study.
Ilie MD, Tabarin A, Vasiljevic A, Bonneville JF, Moreau-Grangé L, Schillo F, Delemer B, Barlier A, Figarella-Branger D, Bisot-Locard S, Santos A, Chanson P, Raverot G
J Clin Endocrinol Metab 2022 Nov 23;107(11):2982-2991. doi: 10.1210/clinem/dgac512. PMID: 36136828
Clinical implications of growth hormone-secreting tumor subtypes.
Kiseljak-Vassiliades K, Shafi S, Kerr JM, Phang TL, Kleinschmidt-DeMasters BK, Wierman ME
Endocrine 2012 Aug;42(1):18-28. Epub 2012 Mar 21 doi: 10.1007/s12020-012-9660-9. PMID: 22434413

Diagnosis

Clinicopathological Analysis of Densely and Sparsely Granulated Somatotroph Tumors of Pituitary.
Wang L, He X, Lu L, Chen L, Peng C, Shao C, Ge R
World Neurosurg 2024 May;185:e713-e720. Epub 2024 Feb 24 doi: 10.1016/j.wneu.2024.02.115. PMID: 38408701
Pituitary neuroendocrine tumors with PIT1/SF1 co-expression show distinct clinicopathological and molecular features.
Dottermusch M, Ryba A, Ricklefs FL, Flitsch J, Schmid S, Glatzel M, Saeger W, Neumann JE, Schüller U
Acta Neuropathol 2024 Jan 16;147(1):16. doi: 10.1007/s00401-024-02686-1. PMID: 38228887Free PMC Article
A current perspective of pituitary adenoma MRI characteristics: a review.
Gruppetta M
Expert Rev Endocrinol Metab 2022 Nov;17(6):499-511. Epub 2022 Nov 13 doi: 10.1080/17446651.2022.2144230. PMID: 36373167
Clinical, hormonal and pathomorphological markers of somatotroph pituitary neuroendocrine tumors predicting the treatment outcome in acromegaly.
Tomasik A, Stelmachowska-Banaś M, Maksymowicz M, Czajka-Oraniec I, Raczkiewicz D, Zieliński G, Kunicki J, Zgliczyński W
Front Endocrinol (Lausanne) 2022;13:957301. Epub 2022 Sep 16 doi: 10.3389/fendo.2022.957301. PMID: 36187106Free PMC Article
Pathological markers of somatotroph pituitary neuroendocrine tumors predicting the response to medical treatment.
Trouillas J, Vasiljevic A, Lapoirie M, Chinezu L, Jouanneau E, Raverot G
Minerva Endocrinol 2019 Jun;44(2):129-136. Epub 2018 Dec 7 doi: 10.23736/S0391-1977.18.02933-4. PMID: 30531694

Therapy

Clinical and prognostic significance of granulation patterns in somatotroph adenomas/tumors of the pituitary: a meta-analysis.
Vuong HG, Dunn IF
Pituitary 2023 Dec;26(6):653-659. Epub 2023 Sep 21 doi: 10.1007/s11102-023-01353-0. PMID: 37735314
Clinical, hormonal and pathomorphological markers of somatotroph pituitary neuroendocrine tumors predicting the treatment outcome in acromegaly.
Tomasik A, Stelmachowska-Banaś M, Maksymowicz M, Czajka-Oraniec I, Raczkiewicz D, Zieliński G, Kunicki J, Zgliczyński W
Front Endocrinol (Lausanne) 2022;13:957301. Epub 2022 Sep 16 doi: 10.3389/fendo.2022.957301. PMID: 36187106Free PMC Article
Predictive Factors of Somatostatin Receptor Ligand Response in Acromegaly-A Prospective Study.
Ilie MD, Tabarin A, Vasiljevic A, Bonneville JF, Moreau-Grangé L, Schillo F, Delemer B, Barlier A, Figarella-Branger D, Bisot-Locard S, Santos A, Chanson P, Raverot G
J Clin Endocrinol Metab 2022 Nov 23;107(11):2982-2991. doi: 10.1210/clinem/dgac512. PMID: 36136828
Growth hormone tumor histological subtypes predict response to surgical and medical therapy.
Kiseljak-Vassiliades K, Carlson NE, Borges MT, Kleinschmidt-DeMasters BK, Lillehei KO, Kerr JM, Wierman ME
Endocrine 2015 May;49(1):231-41. Epub 2014 Aug 17 doi: 10.1007/s12020-014-0383-y. PMID: 25129651Free PMC Article
Stereotactic radiosurgery for acromegaly: outcomes by adenoma subtype.
Lee CC, Vance ML, Lopes MB, Xu Z, Chen CJ, Sheehan J
Pituitary 2015 Jun;18(3):326-34. doi: 10.1007/s11102-014-0578-5. PMID: 24925503

Prognosis

Clinicopathological Analysis of Densely and Sparsely Granulated Somatotroph Tumors of Pituitary.
Wang L, He X, Lu L, Chen L, Peng C, Shao C, Ge R
World Neurosurg 2024 May;185:e713-e720. Epub 2024 Feb 24 doi: 10.1016/j.wneu.2024.02.115. PMID: 38408701
Pituitary neuroendocrine tumors with PIT1/SF1 co-expression show distinct clinicopathological and molecular features.
Dottermusch M, Ryba A, Ricklefs FL, Flitsch J, Schmid S, Glatzel M, Saeger W, Neumann JE, Schüller U
Acta Neuropathol 2024 Jan 16;147(1):16. doi: 10.1007/s00401-024-02686-1. PMID: 38228887Free PMC Article
A current perspective of pituitary adenoma MRI characteristics: a review.
Gruppetta M
Expert Rev Endocrinol Metab 2022 Nov;17(6):499-511. Epub 2022 Nov 13 doi: 10.1080/17446651.2022.2144230. PMID: 36373167
Predictive Factors of Somatostatin Receptor Ligand Response in Acromegaly-A Prospective Study.
Ilie MD, Tabarin A, Vasiljevic A, Bonneville JF, Moreau-Grangé L, Schillo F, Delemer B, Barlier A, Figarella-Branger D, Bisot-Locard S, Santos A, Chanson P, Raverot G
J Clin Endocrinol Metab 2022 Nov 23;107(11):2982-2991. doi: 10.1210/clinem/dgac512. PMID: 36136828
Pathological markers of somatotroph pituitary neuroendocrine tumors predicting the response to medical treatment.
Trouillas J, Vasiljevic A, Lapoirie M, Chinezu L, Jouanneau E, Raverot G
Minerva Endocrinol 2019 Jun;44(2):129-136. Epub 2018 Dec 7 doi: 10.23736/S0391-1977.18.02933-4. PMID: 30531694

Clinical prediction guides

Clinicopathological Analysis of Densely and Sparsely Granulated Somatotroph Tumors of Pituitary.
Wang L, He X, Lu L, Chen L, Peng C, Shao C, Ge R
World Neurosurg 2024 May;185:e713-e720. Epub 2024 Feb 24 doi: 10.1016/j.wneu.2024.02.115. PMID: 38408701
A current perspective of pituitary adenoma MRI characteristics: a review.
Gruppetta M
Expert Rev Endocrinol Metab 2022 Nov;17(6):499-511. Epub 2022 Nov 13 doi: 10.1080/17446651.2022.2144230. PMID: 36373167
Clinical, hormonal and pathomorphological markers of somatotroph pituitary neuroendocrine tumors predicting the treatment outcome in acromegaly.
Tomasik A, Stelmachowska-Banaś M, Maksymowicz M, Czajka-Oraniec I, Raczkiewicz D, Zieliński G, Kunicki J, Zgliczyński W
Front Endocrinol (Lausanne) 2022;13:957301. Epub 2022 Sep 16 doi: 10.3389/fendo.2022.957301. PMID: 36187106Free PMC Article
Predictive Factors of Somatostatin Receptor Ligand Response in Acromegaly-A Prospective Study.
Ilie MD, Tabarin A, Vasiljevic A, Bonneville JF, Moreau-Grangé L, Schillo F, Delemer B, Barlier A, Figarella-Branger D, Bisot-Locard S, Santos A, Chanson P, Raverot G
J Clin Endocrinol Metab 2022 Nov 23;107(11):2982-2991. doi: 10.1210/clinem/dgac512. PMID: 36136828
Pathological markers of somatotroph pituitary neuroendocrine tumors predicting the response to medical treatment.
Trouillas J, Vasiljevic A, Lapoirie M, Chinezu L, Jouanneau E, Raverot G
Minerva Endocrinol 2019 Jun;44(2):129-136. Epub 2018 Dec 7 doi: 10.23736/S0391-1977.18.02933-4. PMID: 30531694

Recent systematic reviews

Metabolomics in acromegaly: a systematic review.
Pînzariu O, Georgescu CE
J Investig Med 2023 Aug;71(6):634-645. Epub 2023 May 4 doi: 10.1177/10815589231169452. PMID: 37139720

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...